Humacyte, Inc.
Humacyte, Inc.
Your view on HUMAW
Overview
What the company does, where it operates, and who runs it.
About Humacyte, Inc.
- Industry
- Biotechnology
- Sector
- Healthcare
- CEO
- Laura E. Niklason
- Headquarters
- 2525 East North Carolina Highway 54, Durham, NC, US
- Industry
- Biotechnology
- Sector
- Healthcare
- CEO
- Laura E. Niklason
- Headquarters
- 2525 East North Carolina Highway 54, Durham, NC, US
Humacyte, Inc. is a company dedicated to the creation and production of bioengineered human tissues that are readily available and suitable for implantation. These advanced tissues are intended for the treatment of a variety of diseases and medical conditions, applicable to numerous anatomical sites and therapeutic areas.
The company employs its distinct, proprietary scientific platform to engineer and manufacture human acellular vessels (HAVs). A significant advantage of these HAVs is their capacity to be implanted into patients without triggering an adverse immune response or leading to rejection by the body.
Humacyte is actively developing a diverse portfolio of HAVs, aiming to address needs within the vascular repair, reconstruction, and replacement market.
This encompasses uses in cases of vascular trauma, establishing arteriovenous access for hemodialysis, treating peripheral arterial disease, performing pediatric heart surgery, and executing coronary artery bypass grafting.
Additionally, their technology supports the delivery of cellular therapies, such as pancreatic islet cell transplantation for managing Type 1 diabetes. Established in 2004, Humacyte, Inc. is headquartered in Durham, North Carolina.
Stock Data
Price chart, volume, and trading data.
Fair Value
What FRC thinks it is worth vs. the current price.
Fair value for Humacyte, Inc. from FRC's valuation model, read against the market price. HUMAW last traded at $0.0009; the estimate is read against that market price. The model runs on every stock on the platform and shows the estimate per share and the date it was calculated. A free account covers 3 company valuations a month; a paid subscription is unlimited.
Financial Ratios
Profitability, returns, valuation, and leverage ratios.
Valuation, profitability, liquidity and leverage ratios for Humacyte, Inc.. Starting points for Humacyte, Inc.: EPS -$0.29, beta 2.43 — an Biotechnology name. P/E, P/B, EV/EBITDA, margins, return on equity, current ratio and debt coverage, each shown against the company's own history.
Dividend Analysis
Yield, payout ratio, and dividend coverage metrics.
Dividend history, yield and payout sustainability for Humacyte, Inc.. Humacyte, Inc. does not currently pay a regular dividend, so this section tracks capacity rather than history. Per-share payments, yield over time, payout ratio and growth streak, with coverage measured against free cash flow.
Earnings Analysis
EPS history, beat rate, and upcoming earnings reports.
Reported vs. expected earnings history for Humacyte, Inc.. Trailing twelve-month EPS for Humacyte, Inc. stands at -$0.29. EPS surprises by quarter, revenue against estimates, and the upcoming reporting date.
Analyst Estimates
Analysts' price targets, ratings, and revenue and EPS estimates.
Analyst Ratings
- Strong Buy0
- Buy1
- Hold0
- Sell0
- Strong Sell0
Earnings Estimate
| EPS | Current QtrDec 2026 | Next QtrMar 2027 | Current YearFY Dec 2026 | Next YearFY Dec 2027 |
|---|---|---|---|---|
| Avg. estimate | -$0.09 | -$0.08 | -$0.40 | -$0.24 |
| Low estimate | -$0.13 | -$0.12 | -$0.87 | -$0.53 |
| High estimate | -$0.02 | -$0.02 | -$0.14 | -$0.09 |
| No. of analysts | 1 | 1 | 1 | 1 |
| Year-ago EPS | -$0.15 | -$0.09 | -$0.26 | — |
| Growth | +43.0% | +13.2% | -52.5% | — |
Revenue Estimate
| Revenue | Current QtrDec 2026 | Next QtrMar 2027 | Current YearFY Dec 2026 | Next YearFY Dec 2027 |
|---|---|---|---|---|
| Avg. estimate | $1.84M | $1.93M | $3.51M | $21.73M |
| Low estimate | $714076.00 | $747128.00 | $2.10M | $10.60M |
| High estimate | $2.66M | $2.78M | $5.19M | $43.35M |
| No. of analysts | 5 | 4 | 5 | 5 |
| Year-ago revenue | $467000.00 | $495000.00 | $2.04M | — |
| Growth | +294.5% | +289.4% | +72.3% | — |
Source: Wall Street analysts' published price targets, ratings and estimates, compiled by Financial Modeling Prep; as of Nov 12, 2026. Not FRC research or a recommendation.
Financial Statements
Income statement, balance sheet, and cash flow statements.
Income statement, balance sheet and cash flow history for Humacyte, Inc.. Humacyte, Inc. has reported as a listed company since 2020. Annual and quarterly filings with period-over-period comparison, so you can trace how revenue, margins and cash generation have moved.
Comparables
List of peer companies in the same industry.
Humacyte, Inc. valued side by side against its closest peers. Humacyte, Inc. is measured against Biotechnology peers within the Healthcare sector. Peer-relative multiples and operating metrics, so the valuation is read in the context of its own sector rather than in isolation.
Insider Trading
Recent buying and selling by company executives.
Buying and selling by Humacyte, Inc. executives and directors. Shares of Humacyte, Inc. have traded between $0.0071 and $0.23 over the past 52 weeks — context for the timing of the transactions below. Insider transactions as disclosed to regulators, with role, size and date — the clearest read on how the people running the company are positioned.
News
Latest headlines and market coverage.
Latest headlines and company announcements for Humacyte, Inc.. Coverage tracks Humacyte, Inc. within Biotechnology (Healthcare). Press releases and market coverage, newest first.
Comments
Comments and replies from FRC members about this company.
No comments yet
Be the first to ask a question or say what you make of Humacyte, Inc.